Article
Oncology
Hussein A. Tawbi, Peter A. Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl Lewis, Reena P. Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine Rizzo, Kim A. Margolin
Summary: The combination of nivolumab and ipilimumab shows durable clinical benefit for asymptomatic patients with melanoma brain metastases, but has limited activity in patients with neurological symptoms and/or requiring corticosteroids.
Article
Oncology
Hamid Emamekhoo, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Edward R. Arrowsmith, Joshua Zhang, Jesus Zoco, Jennifer L. Johansen, David K. Leung, Scott S. Tykodi
Summary: The study aimed to evaluate the safety and efficacy of Nivolumab plus Ipilimumab combination therapy in patients with previously untreated advanced renal cell carcinoma and asymptomatic brain metastases. Results showed encouraging antitumor activity of the drug combination with no new safety signals.
Article
Oncology
Takeshi Fukumoto, Nobuyuki Horita
Summary: Tawbi et al. (2021) reported that the N1I3 regimen provided durable survival for patients with active melanoma brain metastases without symptoms, but we investigated whether the N3I1 regimen might have a better safety profile.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Oncology
Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Ornella Cutaia, Giovanni Amato, Alessia Covre, Roberto Camerini, Luana Calabro, Monica Valente, Diana Giannarelli, Mario Mandala, Michele Maio
Summary: The study compared the efficacy of ipilimumab plus nivolumab with fotemustine in treating melanoma patients with brain metastases, showing that ipilimumab plus nivolumab significantly improved overall and long-term survival rates for patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Justin F. Gainor, Gregory A. Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, Helena Linardou, Reyes Bernabe Caro, Mariano Provencio, Bogdan Zurawski, Ki Hyeong Lee, Sang-We Kim, Claudia Caserta, Suresh S. Ramalingam, David R. Spigel, Julie R. Brahmer, Martin Reck, Kenneth J. O'Byrne, Nicolas Girard, Sanjay Popat, Solange Peters, Arteid Memaj, Faith Nathan, Nivedita Aanur, Hossein Borghaei
Summary: This study assessed the safety and efficacy of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large population of patients with metastatic non-small cell lung cancer (NSCLC). The findings showed that the treatment had relatively lower safety in older patients, but discontinuation did not reduce long-term survival in responders.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Felix Pham, Samy Belkaid, Denis Maillet, Cyrille B. Confavreux, Stephane Dalle, Julien Peron
Summary: The presence of baseline bone metastases appears to be associated with worse outcomes in RCC combo-ICI-treated patients, while its effect may not be independent from the inflammatory state. However, bone metastases seem to have no impact on the outcomes of melanoma combo-ICI-treated patients.
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martinez-Marti, Koichi Azuma, Rita Axelrod, Luis G. Paz-Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O'Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, Julie R. Brahmer
Summary: The combination therapy of nivolumab and ipilimumab has shown prolonged overall survival in patients with metastatic NSCLC, regardless of tumor PD-L1 expression. The study also demonstrated that this combination therapy remains effective in patients with baseline brain metastases and has better intracranial efficacy compared to chemotherapy.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
K. J. O'Byrne, K. H. Lee, S-W Kim, K. Park, M. Nishio, H. Sakai, Y. Ohe, T. Fukuhara, J-H Kang, H. Daga, C-J Yu, K. Hotta, H. Tanaka, M. Takeda, T. Yokoyama, F. E. Nathan, J-S Lee
Summary: Nivolumab plus ipilimumab provides durable long-term efficacy benefits as first-line treatment in the Asian subpopulation with advanced non-small cell lung cancer (NSCLC), regardless of tumor PD-L1 expression, particularly in Japanese patients.
Review
Oncology
Lucia Vazquez-Montero, Maria del Carmen Alamo de la Gala, Luis de la Cruz-Merino
Summary: The development of immune checkpoint inhibitors has transformed the treatment of advanced melanoma. Nivolumab plus ipilimumab, along with other immunotherapy options, has shown efficacy for advanced melanoma. However, the combination therapy is associated with severe immune-related toxicity. This article reviews the efficacy and safety of nivolumab plus ipilimumab in advanced melanoma and explores the potential benefits for different patient subgroups.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Andrea B. Apolo, Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burcin Simsek, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri
Summary: This study analyzed the clinical activity of the nivolumab plus ipilimumab plus cabozantinib triplet combination in previously untreated aRCC patients, showing a certain efficacy but the need for monitoring overlapping toxicities.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Lili Mao, Meiyu Fang, Yu Chen, Xiaoting Wei, Jun Cao, Jing Lin, Peng Zhang, Ling Chen, Xiao Cao, Yujun Chen, Jun Guo, Lu Si
Summary: Atezolizumab in combination with bevacizumab shows promising efficacy and manageable safety in patients with advanced mucosal melanoma.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
M. Reck, T. -E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, F. Reyes, P. -J. Souquet, P. De Marchiy, C. Martin, M. Perol, A. Scherpereel, S. Lu, L. Paz-Ares, D. P. Carbone, A. Memaj, S. Marimuthu, X. Zhang, P. Tran, T. John
Summary: The updated data from the phase III CheckMate 9LA trial with a minimum 2-year follow-up show that first-line nivolumab plus ipilimumab with two cycles of chemotherapy continues to provide prolonged overall survival benefits over chemotherapy in advanced non-small-cell lung cancer patients, with manageable safety profile. Improved efficacy outcomes were observed in most subgroups with no new safety signals detected.
Article
Dermatology
Katharina Schumann, Cornelia Mauch, Kai-Christian Klespe, Carmen Loquai, Ulrike Nikfarjam, Max Schlaak, Larissa Akcetin, Peter Koelblinger, Magdalena Hoellwerth, Markus Meissner, Guelcin Mengi, Andreas Dominik Braun, Miriam Mengoni, Reinhard Dummer, Joanna Mangana, Mihaela-Anca Sindrilaru, Dan Radmann, Christine Hafner, Johann Freund, Klemens Rappersberger, Felix Weihsengruber, Frank Meiss, Lydia Reinhardt, Friedegund Meier, Barbara Rainer, Erika Richtig, Julia Maria Ressler, Christoph Hoeller, Thomas Eigentler, Teresa Amaral, Wiebke K. Peitsch, Uwe Hillen, Wolfgang Harth, Fabian Ziller, Kerstin Schatton, Thilo Gambichler, Laura Susok, Lara Valeska Maul, Heinz Laubli, Dirk Debus, Carsten Weishaupt, Sevil Boerger, Katharina Sievers, Sebastian Haferkamp, Veronika Zenderowski, Van Anh Nguyen, Marina Wanner, Ralf Gutzmer, Patrick Terheyden, Katharina Kaehler, Steffen Emmert, Alexander Thiem, Michael Sachse, Silke Gercken-Riedel, Kjell Matthias Kaune, Kai-Martin Thoms, Lucie Heinzerling, Markus Vincent Heppt, Sabine Tratzmiller, Wolfram Hoetzenecker, Angela Oellinger, Andreas Steiner, Tobias Peinhaupt, Maurizio Podda, Sabine Schmid, Uwe Wollina, Tilo Biedermann, Christian Posch
Summary: This real-world study examines the clinical outcomes of adjuvant melanoma treatment using PD-1 antibodies and BRAF + MEK inhibitors in specialized skin cancer centers in Germany, Austria, and Switzerland. The results show that patients treated with PD-1 antibodies have a lower 12-month recurrence rate compared to patients treated with BRAF + MEK inhibitors. Additionally, PD-1 antibody treatment is not affected by BRAF mutation status.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Oncology
Anna Lorenz, Mateusz Kozlowski, Sebastian Lenkiewicz, Sebastian Kwiatkowski, Aneta Cymbaluk-Ploska
Summary: Melanoma of the vulva and vagina is a rare neoplasm with a poor prognosis. Immunotherapy, a rapidly developing cancer treatment method, has limited effectiveness for this rare type of melanoma.
